Popular weight loss drugs could curb addictions and more

KANSAS CITY, Mo. (KCTV) - Weight loss drugs may have more benefits than some realize.

According to a new observational study by St. Luke’s Mid-America Heart Institute in Kansas City, Missouri, researchers analyzed Mounjaro, Zepbound, Ozempic, and Wegovy. These drugs are typically used to treat diabetes and obesity but now scientists say they may also reduce cravings of other kinds.

There is evidence these drugs, classified as GLP-1 receptor agonists, can hedge off cravings for recreational drugs, alcohol, and overall addictive tendencies.

Dr. James O’Keefe, a cardiologist at St. Luke’s Mid-America Heart Institute said this class of drugs is proving the most influential of the century.

“The thing most amazing about them is how these drugs suddenly alter the dopamine-related reward pathway in the brain making us less of a slave to cravings. Today, 73% of Americans are obese or overweight, and the death rate from substance abuse is twice as high in the U.S. as the next highest nation,” said O’Keefe.

The good news lies not just with reducing weight and cravings but evidence exists showing GLP-1 meds are beneficial for a whole host of issues including reducing heart attack and stroke risk, as well as liver and kidney failure. The analyses showed they also can reduce arthritis pain, the need for t replacement, and improve sleep apnea.

Additionally, researchers noted GLP-1s are showing promise in reducing the risk of neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

O’Keefe said the drugs are safe and effective but should only be taken under the supervision of a licensed provider with experience prescribing them.

ALSO READ: Report reveals more work to be done to ensure best chances for infants in KC

Copyright 2025 KCTV. All rights reserved.